• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与特发性病例相比,具有路易体病理的 G2019S LRRK2 帕金森病大脑中 α-突触核蛋白的可溶性和聚集特性存在差异。

Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.

机构信息

Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, UK.

出版信息

Neurobiol Dis. 2013 Oct;58:183-90. doi: 10.1016/j.nbd.2013.05.017. Epub 2013 Jun 5.

DOI:10.1016/j.nbd.2013.05.017
PMID:23747310
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3752970/
Abstract

Mutations in LRRK2 are the most common genetic cause of Parkinson's disease (PD). The most prevalent LRRK2 mutation is the G2019S coding change, located in the kinase domain of this complex multi-domain protein. The majority of G2019S autopsy cases feature typical Lewy Body pathology with a clinical phenotype almost indistinguishable from idiopathic PD (iPD). Here we have investigated the biochemical characteristics of α-synuclein in G2019S LRRK2 PD post-mortem material, in comparison to pathology-matched iPD. Immunohistochemistry with pS129 α-synuclein antibody showed that the medulla is heavily affected with pathology in G2019S PD whilst the basal ganglia (BG), limbic and frontal cortical regions demonstrated comparable pathology scores between G2019S PD and iPD. Significantly lower levels of the highly aggregated α-synuclein species in urea-SDS fractions were observed in G2019S cases compared to iPD in the BG and limbic cortex. Our data, albeit from a small number of cases, highlight a difference in the biochemical properties of aggregated α-synuclein in G2019S linked PD compared to iPD, despite a similar histopathological presentation. This divergence in solubility is most notable in the basal ganglia, a region that is affected preclinically and is damaged before overt dopaminergic cell death.

摘要

LRRK2 突变是帕金森病 (PD) 的最常见遗传原因。最常见的 LRRK2 突变是 G2019S 编码变化,位于该复杂多结构域蛋白的激酶结构域中。大多数 G2019S 尸检病例具有典型的路易体病理学特征,其临床表型与特发性 PD (iPD) 几乎无法区分。在这里,我们研究了 G2019S LRRK2 PD 死后组织中 α-突触核蛋白的生化特征,与病理学匹配的 iPD 进行了比较。用 pS129 α-突触核蛋白抗体进行免疫组织化学染色显示,G2019S PD 的髓质受到严重影响,而基底节 (BG)、边缘和额皮质区域的病理学评分在 G2019S PD 和 iPD 之间具有可比性。与 iPD 相比,BG 和边缘皮质中的 G2019S 病例中尿素-SDS 级分中高度聚集的 α-突触核蛋白的水平显著降低。尽管病例数量较少,但我们的数据突出表明,与 iPD 相比,G2019S 相关 PD 中聚集的 α-突触核蛋白的生化特性存在差异,尽管其组织病理学表现相似。这种溶解度的差异在基底节最为明显,基底节是一个在临床前受到影响并在多巴胺能细胞死亡之前受损的区域。

相似文献

1
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.与特发性病例相比,具有路易体病理的 G2019S LRRK2 帕金森病大脑中 α-突触核蛋白的可溶性和聚集特性存在差异。
Neurobiol Dis. 2013 Oct;58:183-90. doi: 10.1016/j.nbd.2013.05.017. Epub 2013 Jun 5.
2
Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.分析具有路易体病理的 G2019S LRRK2 帕金森病大脑中的巨自噬相关蛋白。
Brain Res. 2018 Dec 15;1701:75-84. doi: 10.1016/j.brainres.2018.07.023. Epub 2018 Jul 25.
3
Widespread distribution of α-synuclein oligomers in LRRK2-related Parkinson's disease.α-突触核蛋白寡聚体在与富亮氨酸重复激酶2(LRRK2)相关的帕金森病中的广泛分布。
Acta Neuropathol. 2025 May 2;149(1):42. doi: 10.1007/s00401-025-02872-9.
4
Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.LRRK2 基因突变相关帕金森病但无认知障碍患者的大脑皮层参与。
Acta Neuropathol. 2010 Aug;120(2):155-67. doi: 10.1007/s00401-010-0669-y. Epub 2010 Mar 16.
5
Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.腺病毒介导的 G2019S LRRK2 的表达以激酶依赖的方式在帕金森病大鼠模型中诱导纹状体病理学。
Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019. Epub 2015 Feb 28.
6
LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.LRRK2 在特发性和 G2019S 阳性帕金森病患者中的表达:形态学和定量研究。
Neuropathol Appl Neurobiol. 2011 Dec;37(7):777-90. doi: 10.1111/j.1365-2990.2011.01187.x.
7
G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.G2019S-LRRK2表达增强α-突触核蛋白在神经元内聚集体中的隔离。
J Neurosci. 2016 Jul 13;36(28):7415-27. doi: 10.1523/JNEUROSCI.3642-15.2016.
8
Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases.路易体阴性的LRRK2突变病例中存在大量非包涵体型α-突触核蛋白病理改变。
Acta Neuropathol. 2025 May 2;149(1):41. doi: 10.1007/s00401-025-02871-w.
9
G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.导致无路易小体帕金森病的G2019S LRRK2突变。
J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8. doi: 10.1136/jnnp.2006.107904. Epub 2007 Jan 8.
10
LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.LRRK2 活性不会显著改变原代神经元中的 α-突触核蛋白病理。
Acta Neuropathol Commun. 2018 May 31;6(1):45. doi: 10.1186/s40478-018-0550-0.

引用本文的文献

1
Alpha-Synuclein Fails to Form Aggregates in Endocytosis-Defective Fission Yeast Strains, ∆ and ∆ .α-突触核蛋白在胞吞作用缺陷型裂殖酵母菌株∆和∆中无法形成聚集体。
MicroPubl Biol. 2025 Jan 21;2025. doi: 10.17912/micropub.biology.001479. eCollection 2025.
2
Peripheral cutaneous synucleinopathy characteristics in genetic Parkinson's disease.遗传性帕金森病的外周皮肤α-突触核蛋白病特征
Front Neurol. 2024 May 1;15:1404492. doi: 10.3389/fneur.2024.1404492. eCollection 2024.
3
Prospective Role of PAK6 and 14-3-3γ as Biomarkers for Parkinson's Disease.

本文引用的文献

1
LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.LRRK2 与帕金森病大脑中α-突触核蛋白的相互作用及在细胞模型中的作用。
J Mol Med (Berl). 2013 Apr;91(4):513-22. doi: 10.1007/s00109-012-0984-y. Epub 2012 Nov 27.
2
Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations.哺乳动物大脑中 4E-BP1 的磷酸化不受 LRRK2 表达或致病突变的影响。
PLoS One. 2012;7(10):e47784. doi: 10.1371/journal.pone.0047784. Epub 2012 Oct 17.
3
LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6.
PAK6 和 14-3-3γ 作为帕金森病生物标志物的前瞻性作用。
J Parkinsons Dis. 2024;14(3):495-506. doi: 10.3233/JPD-230402.
4
Biochemical Fractionation of Human α-Synuclein in a Model of Synucleinopathies.人α-突触核蛋白在突触核蛋白病模型中的生化分离。
Int J Mol Sci. 2024 Mar 25;25(7):3643. doi: 10.3390/ijms25073643.
5
ATP13A2 (PARK9) and basal ganglia function.ATP13A2(PARK9)与基底神经节功能。
Front Neurol. 2024 Jan 5;14:1252400. doi: 10.3389/fneur.2023.1252400. eCollection 2023.
6
Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases.一种扩展抗体工具集的开发与验证,该工具集可捕捉路易体病中α-突触核蛋白的病理多样性。
NPJ Parkinsons Dis. 2023 Dec 7;9(1):161. doi: 10.1038/s41531-023-00604-y.
7
Endogenous Alpha-Synuclein is Essential for the Transfer of Pathology by Exosome-Enriched Extracellular Vesicles, Following Inoculation with Preformed Fibrils in vivo.内源性α-突触核蛋白对于富含外泌体的细胞外囊泡在体内接种预形成纤维后通过外泌体传递病理学是必需的。
Aging Dis. 2024 Apr 1;15(2):869-892. doi: 10.14336/AD.2023.0614.
8
DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson's disease.DOPAL引发帕金森病中α-突触核蛋白依赖性的蛋白稳态受损和神经元突起退化。
NPJ Parkinsons Dis. 2023 Mar 25;9(1):42. doi: 10.1038/s41531-023-00485-1.
9
LRRK2 and Proteostasis in Parkinson's Disease.LRRK2 与帕金森病中的蛋白稳态
Int J Mol Sci. 2022 Jun 18;23(12):6808. doi: 10.3390/ijms23126808.
10
Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease.LRRK2 相关帕金森病中谷氨酸转运体的转运受损。
Acta Neuropathol. 2022 Jul;144(1):81-106. doi: 10.1007/s00401-022-02437-0. Epub 2022 May 21.
LRRK2 作为 Wnt 信号支架发挥作用,连接细胞质蛋白和膜定位的 LRP6。
Hum Mol Genet. 2012 Nov 15;21(22):4966-79. doi: 10.1093/hmg/dds342. Epub 2012 Aug 16.
4
Age at onset in LRRK2-associated PD is modified by SNCA variants.LRRK2 相关 PD 的发病年龄受 SNCA 变异的影响。
J Mol Neurosci. 2012 Sep;48(1):245-7. doi: 10.1007/s12031-012-9820-7. Epub 2012 Jun 6.
5
Direct observation of the interconversion of normal and toxic forms of α-synuclein.α-突触核蛋白正常形式和毒性形式相互转换的直接观察。
Cell. 2012 May 25;149(5):1048-59. doi: 10.1016/j.cell.2012.03.037.
6
High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain.LRRK2 水平升高未能诱导或加重小鼠脑内的神经元α-突触核蛋白病。
PLoS One. 2012;7(5):e36581. doi: 10.1371/journal.pone.0036581. Epub 2012 May 15.
7
GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.帕金森病相关 LRRK2 的 GTPase 活性和神经元毒性受 ArfGAP1 调节。
PLoS Genet. 2012;8(2):e1002526. doi: 10.1371/journal.pgen.1002526. Epub 2012 Feb 9.
8
Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.在 A53T α-突触核蛋白转基因小鼠模型中,神经退行性表型与 LRRK2 无关。
Hum Mol Genet. 2012 Jun 1;21(11):2420-31. doi: 10.1093/hmg/dds057. Epub 2012 Feb 21.
9
Reduced content of α-synuclein in peripheral blood leukocytes of patients with LRRK2-associated Parkinson's disease.LRRK2相关帕金森病患者外周血白细胞中α-突触核蛋白含量降低。
Bull Exp Biol Med. 2011 Apr;150(6):679-81. doi: 10.1007/s10517-011-1221-3.
10
Clinical and pathological characteristics of LRRK2 G2019S patients with PD.LRRK2 G2019S 帕金森病患者的临床和病理特征。
J Mol Neurosci. 2012 May;47(1):139-43. doi: 10.1007/s12031-011-9696-y. Epub 2011 Dec 23.